Our investigations, encompassing subcutaneous tumor xenografts and HE staining analyses, revealed that, relative to the NC group, tumor volume and area markedly escalated in the ACVR2A-inhibitor cohort, whereas a significant diminution was observed in the ACVR2A-mimic group, suggesting ACVR2A’s inhibitory effect on CRC progression. Here, ACVR2A is linked to colorectal carcinoma.